At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
90Y-hPAM4biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Dose-Escalating Study to Investigate the Safety, Tolerability, Pharmacokinetics and Dosimetry of a Single Dose of 90YHumanized PAM4 IgG in Patients With Locally Advanced/Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating 90Y-hPAM4 for Pancreatic Cancer. Completed, enrolled 21 participants across 4 sites.
Detailed Summary
Safety study to determine highest dose of 90Y-hPAM4 can be safety administered
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2004
Primary CompletionOct 2007
First PostedJan 2008
TodayJul 2026
First PostedJan 17, 2008
Enrollment StartAug 1, 2004
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.5 years ago
Interventions
90Y-hPAM4biological
Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.